Close this search box.

Arvinas hires Berkowitz as CMO

ARTICLE | Management Tracks

Plus: BoA veteran Setia joins MapLight as CFO, and updates from Ocugen, Clearside, Telum, SmartCella, AstriVax and Solu

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst 

March 19, 2024 11:37 PM UTC

Noah Berkowitz became CMO at Arvinas Inc. (NASDAQ:ARVN), which is developing targeted protein degraders. Berkowitz was SVP, development unit head, hematology at Bristol Myers Squibb Co. (NYSE:BMY) and succeeds Ron Peck, who is leaving Arvinas to pursue other opportunities.

MapLight Therapeutics Inc. hired Bank of America Securities veteran Vishwas Setia to succeed CFO Jonathan Gillis, a move that could signal the CNS disorders company is positioning itself to go public.  MapLight, which has raised at least $275 million in venture cash, has investors that include Novo Holdings A/S, 5AM Ventures and Cowen Healthcare Investments. Gillis will become MapLight’s chief administrative and accounting officer…